Summary of Novocure Conference Call Company Overview - **Company**: Novocure (NasdaqGS: NVCR) - **Founded**: 25 years ago - **Core Insight**: Cancer cells possess unique electrical properties distinct from healthy cells, leading to the development of Tumor Treating Fields (TTFields) as a treatment for glioblastoma, non-small cell lung cancer, and pancreatic cancer [4][6][11] Key Points and Arguments Business Strategy and Focus - **CEO Transition**: Frank Leonard became CEO in December 2025, emphasizing a shift towards commercial viability alongside clinical development [6][7] - **Therapeutic Approach**: TTFields is a physical treatment method with minimal toxicity, allowing for broader application across various tumor types [6][7] - **Market Penetration**: Currently, Novocure has a 40% penetration rate in established markets for glioblastoma (GBM) with potential for growth through improved execution and data [18][22] Clinical Development and Trials - **TRIDENT Study**: A 950-patient trial for newly diagnosed GBM, aiming to assess the effectiveness of TTFields combined with radiation therapy [27][29] - **Pancreatic Cancer Launch**: Approved for locally advanced pancreatic cancer, with an estimated total addressable market (TAM) of around 15,000 patients annually [33][34] - **Ongoing Trials**: PANOVA-4 trial in metastatic pancreatic cancer, exploring the combination of TTFields with chemotherapy and immune checkpoint inhibitors [55][61] Financial Outlook - **Revenue Projections**: Expected revenue for 2026 is between $675 million and $705 million, primarily driven by GBM and new indications [64] - **Growth Drivers**: Anticipated double-digit revenue growth from GBM and pancreatic cancer, with a focus on disciplined operating expenses [66][69] Market Dynamics and Competitive Landscape - **KRAS Inhibitors**: Novocure acknowledges the development of KRAS inhibitors for pancreatic cancer but emphasizes its unique position as the first branded product for locally advanced cases [46][47] - **Patient Compliance**: The company is focusing on ensuring that treatment protocols are manageable for patients, particularly in pancreatic cancer where patient motivation is high [16][34] Additional Important Insights - **Adverse Events**: TTFields has shown a favorable safety profile with minimal adverse events, primarily skin irritation [48][54] - **Multi-Indication Strategy**: Novocure is leveraging its trained field force from previous launches to promote its pancreatic cancer treatment effectively [43][44] - **Future Directions**: The company plans to explore collaborations with KRAS inhibitor developers and adapt treatment protocols to enhance patient experience and compliance [47][57] This summary encapsulates the critical insights and strategic directions discussed during the Novocure conference call, highlighting the company's focus on expanding its market presence and enhancing treatment options for cancer patients.

Key Takeaways NVCR wins Japan National Health Insurance reimbursement for Optune Lua in NSCLC patients.Coverage in Japan could expand patient access and drive adoption of Novocure's TTFields therapy platform.NVCR's Optune Lua uses alternating electric fields to disrupt cancer cell division in NSCLC.Novocure (NVCR) recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program.In Japan, Optune Lua is ind ...

Core Insights - NovoCure Limited achieved record net revenue of $655 million in 2025, driven by substantial active patient growth in international markets like France and Japan [4] - The company transitioned to a multi-indication platform following FDA approval of Optune Pax for locally advanced pancreatic cancer in a record 180-day review cycle [4] - Projected 2026 revenue is estimated to be between $675 million and $705 million, assuming low to mid-single-digit growth in the core glioblastoma (GBM) business and an additional $15 million to $25 million from new indications [4] Financial Performance - The gross margin decreased to 75% for 2025, attributed to lower prior-period collections and increased costs from HIV rates and tariffs [5] - The company is targeting a range of negative $20 million to breakeven for adjusted EBITDA in full-year 2026 through diligent expense management [4] Strategic Initiatives - The leadership team was restructured to combine scientific and clinical organizations under a dual Chief Innovation and Medical Officer role to accelerate R&D-to-clinical cycles [4] - Planned international expansion includes product launches in Japan, Spain, Czechia, and British Columbia to diversify the global revenue base [4] - Marketing spend for Optune Lua in the U.S. and Germany was rightsized due to slower-than-projected adoption in the non-small cell lung cancer market [4] Clinical Development - Anticipated clinical catalysts include Phase II PANOVA-4 top-line data in March and Phase III TRIDENT data in the second quarter of 2026 [4] - Enrollment for the Phase III KEYNOTE D58 trial in newly diagnosed GBM is expected to be completed by the end of 2026 [4] Operational Challenges - Addressed a temporary Medicare billing administrative issue, securing retroactive reinstatement to ensure no negative impact on revenue recognition [4] - Acknowledged a 1-2 year lag in routine commercial insurance coverage for new indications, requiring initial reliance on appeals and NCCN guideline inclusion [4]

分组1 - NovoCure reported a quarterly loss of $0.22 per share, better than the Zacks Consensus Estimate of a loss of $0.41, and improved from a loss of $0.61 per share a year ago, resulting in an earnings surprise of +46.01% [1] - The company achieved revenues of $174.35 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.83% and increasing from $161.27 million year-over-year [2] - NovoCure has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has gained approximately 15.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.5% [3] - The company's earnings outlook will be crucial for future stock performance, with current consensus EPS estimates at -$0.58 for the coming quarter and -$1.62 for the current fiscal year [4][7] - The Zacks Industry Rank places the Medical - Biomedical and Genetics sector in the top 36% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Core Insights - NovoCure's glioblastoma (GBM) business remains a core focus, with active patient growth in major markets, particularly outside the U.S. [1] - The company reported record net revenue of $655 million for 2025, an 8% increase from 2024, and anticipates continued momentum into 2026 [4][11] - Management expects 2026 to be a "catalyst-rich" year with multiple regulatory and clinical milestones, including the FDA approval of Optune Pax for locally advanced pancreatic cancer [3][5] Financial Performance - Fourth-quarter net revenue was $174 million, contributing to the full-year net revenue of $655 million, both reflecting an 8% year-over-year growth [11] - Gross margin for 2025 was 75%, down from 77% in 2024, attributed to lower prior-period collections and higher costs [14] - The company reported a net loss of $136 million for the year, with an adjusted EBITDA of negative $34 million [16] Market Opportunities and Product Launches - NovoCure is preparing to launch Optune Pax in the U.S. and Japan, with an estimated total addressable market of about 15,000 patients annually for locally advanced pancreatic cancer [9][6] - The company expects modest contributions from new GBM markets and $15 million to $25 million in net revenue from non-GBM products in 2026 [17] - Optune Lua generated $10.4 million in revenue for the full year, with $5.8 million from non-small cell lung cancer patients [12] Strategic Changes and Leadership - CEO Frank Leonard highlighted 2025 as the company's most successful year, with plans to evolve into a "multi-indication platform company" [2] - Following the resignation of the Chief Medical Officer, the company combined its scientific and clinical organizations to enhance R&D execution [2] - The company is leveraging its existing sales force for the Optune Pax launch without adding incremental sales headcount [8]

Financial Data and Key Metrics Changes - The company generated a record $655 million in net revenues for 2025, representing an 8% increase from 2024 [5][17] - Fourth quarter net revenue was $174 million, also reflecting an 8% year-over-year growth [17] - Adjusted EBITDA was negative $34 million for the full year, with a guidance of -$20 million to break even for 2026 [21][23] Business Line Data and Key Metrics Changes - Optune Lua revenue for the full year was $10.4 million, including $5.8 million from non-small cell lung cancer patients [17] - The company expects contributions from new indications, including Optune Lua and Optune Pax, to be in the range of $15 million to $25 million for 2026 [19][29] Market Data and Key Metrics Changes - Active patient growth in major markets included 10% in Germany, 19% in France, and 29% in Japan, while the U.S. saw a 4% growth [11] - The company anticipates modest contributions from new market launches in Spain, Czechia, and British Columbia [12] Company Strategy and Development Direction - The company aims to drive profitability and has set a goal to reach adjusted EBITDA breakeven in 2026 [23][56] - The recent approval of Optune Pax for locally advanced pancreatic cancer is expected to significantly contribute to long-term growth [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Optune products and the importance of establishing coverage policies with payers [49] - The company is focused on maintaining momentum and achieving regulatory, clinical, and commercial milestones in 2026 [7][55] Other Important Information - The company resolved a Medicare billing issue with CMS, ensuring no negative impact on revenue recognition [18] - Dr. Nicolas Leupin resigned as Chief Medical Officer, and Dr. Uri Weinberg will assume the role, combining scientific and clinical organizations to enhance R&D execution [9] Q&A Session Summary Question: Why is the company providing guidance now? - Management indicated that setting clear expectations for growth is essential as the company matures in the public market [27][28] Question: What are the assumptions behind the revenue guidance? - The guidance includes growth from established GBM markets, new markets, and contributions from new indications [29][30] Question: How will Optune Pax be prescribed based on the approved label? - The company plans to target a highly motivated patient population with limited treatment options, emphasizing the unique value proposition of Optune Pax [39] Question: How much sales force is allocated for Optune Pax? - The existing sales team trained for Optune Lua will lead the Optune Pax launch without adding new headcount [44]

Financial Data and Key Metrics Changes - The company generated a record $655 million in net revenues for 2025, an 8% increase from 2024 [5][17] - Fourth quarter net revenue was $174 million, also reflecting an 8% year-over-year growth [17] - Gross margin for Q4 was 76% and 75% for the full year, down from 79% and 77% in 2024, primarily due to decreased prior period collections in the US and increased costs [19] - The net loss for Q4 was $24 million, with a loss per share of $0.22, and a full-year net loss of $136 million, or $1.22 per share [21] Business Line Data and Key Metrics Changes - Optune Lua revenue for the full year was $10.4 million, including $5.8 million from non-small cell lung cancer patients [17] - The company recognized $3.5 million from Optune Lua claims in Q4, including $2.4 million from non-small cell lung cancer [17] - Research and development costs increased by 19% in Q4 to $61 million, driven by costs related to phase 3 trials [20] Market Data and Key Metrics Changes - Active patient growth in major markets included 10% in Germany, 19% in France, and 29% in Japan, while the US saw a 4% growth [11] - The company expects growth rates to stabilize in the low to mid-single digits as markets mature [11] Company Strategy and Development Direction - The company aims to drive profitable growth and achieve adjusted EBITDA breakeven in 2026 [22] - New product launches are planned for Optune Gio in Spain, Czechia, and British Columbia, and Optune Lua in Japan [8][12] - The approval of Optune Pax for locally advanced pancreatic cancer is expected to significantly contribute to long-term growth [6][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming regulatory, clinical, and commercial milestones for 2026, including the approval of Optune Pax and anticipated data readouts from ongoing trials [6][54] - The company is focused on establishing coverage policies for new indications and believes that the market opportunity for pancreatic cancer is significant [39][49] Other Important Information - The Chief Medical Officer resigned, and the company combined its scientific and clinical organizations to enhance R&D execution [9] - The company resolved a Medicare billing issue with CMS, ensuring no negative impact on revenue recognition [18] Q&A Session Summary Question: Guidance for 2026 - Management indicated that providing guidance now reflects a commitment to returning to steady growth and achieving adjusted EBITDA breakeven [26][27] Question: Optune Gio Revenue Growth - Management clarified that the guidance for low to mid-single digit growth is not a signal of market moderation but reflects the potential for increased patient prescriptions [34] Question: Optune Pax Prescription Strategy - Management emphasized the importance of targeting a highly motivated patient population for Optune Pax and leveraging existing sales teams for the launch [39][44] Question: Sales Force Allocation for Optune Pax - The existing sales team trained for Optune Lua will lead the Optune Pax launch without adding new headcount [44] Question: Revenue Contributions from Optune Pax - Management noted that revenue from Optune Pax will initially lag as coverage policies are established, with expectations for routine coverage taking 1-2 years [49][50]

forward -looking statements In addition to historical facts or statements of current condition, this presentation may contain forward - looking statements. Fo rward - looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding anticipated scientific pro gress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, man ufa cturing developmen ...

Revenue and Growth - Net revenues are primarily derived from patients using the company's products, with potential net revenues per patient influenced by payment security, monthly fees, and duration of therapy [311]. - Net revenues increased by $50.1 million, or 8%, to $655.4 million for the year ended December 31, 2025, compared to $605.2 million in 2024 [343]. - The company reported net revenues of $655.4 million for the year ended December 31, 2025, an increase of 8.5% from $605.2 million in 2024 and 28.7% from $509.3 million in 2023 [386]. - Active patients at period end increased to 4,620 in 2025 from 4,126 in 2024, representing a growth of 12% [339]. - Prescriptions received in the United States rose to 4,183 in 2025 from 3,837 in 2024, an increase of 9% [340]. Expenses and Costs - Research, development, and clinical study expenses totaled $224.5 million in 2025, a slight increase from $209.6 million in 2024, with significant investments in clinical programs for solid tumors [316]. - The company incurred operating expenses primarily related to personnel costs, which are significant across research, development, sales, and general administration [313]. - Sales and marketing expenses are expected to remain significant as the company continues commercialization efforts in North America, the EU, and Japan [318]. - Cost of revenues increased by $29.7 million, or 22%, to $166.9 million in 2025, primarily due to a 9% growth in Optune Gio active patients [344]. - General and administrative expenses decreased by $12.2 million, or 6%, to $177.7 million in 2025, mainly due to lower share-based compensation [351]. Profitability and Financial Performance - Adjusted EBITDA decreased by $35.1 million to $(34.3) million for the year ended December 31, 2025, from $0.8 million in 2024, primarily due to increased operating expenses [356]. - The company experienced a net loss of $136.2 million for the year ended December 31, 2025, compared to a net loss of $168.6 million in 2024 and $207.0 million in 2023 [386]. - Income tax expenses decreased by $37.5 million, or 100%, resulting in a tax benefit of $0.0 million for the year ended December 31, 2025, compared to a tax expense of $37.5 million in 2024 [353]. - Financial income, net decreased by $21.8 million, or 55%, to $17.5 million for the year ended December 31, 2025, from $39.3 million in 2024 [352]. Cash Flow and Financial Position - As of December 31, 2025, the company had $93.5 million in cash and cash equivalents and $354.1 million in short-term investments, totaling $447.7 million, a decrease of $512.2 million compared to $959.9 million at the end of 2024 [358]. - Net cash used in operating activities was $49.0 million for the year ended December 31, 2025, compared to $26.4 million in 2024, an increase of $22.1 million [362]. - Net cash provided by investing activities was $437.3 million for the year ended December 31, 2025, compared to net cash used of $140.2 million in 2024, primarily due to net proceeds from short-term investments [366]. - Net cash used in financing activities was $451.3 million for the year ended December 31, 2025, compared to net cash provided of $90.3 million in 2024, mainly due to the repayment of a convertible note [368]. - The company has an accumulated deficit of $1,290.4 million as of December 31, 2025, reflecting significant losses since its founding [357]. Clinical Programs and Research - The company is prioritizing clinical programs with high value potential in glioblastoma, pancreatic cancer, and non-small cell lung cancer [317]. - The Phase 3 METIS clinical trial showed that patients treated with TTFields therapy and best supportive care experienced a 28% lower risk of intracranial progression compared to those receiving best supportive care alone [379]. - The median time to intracranial progression was 15.0 months for patients treated with TTFields therapy and best supportive care, compared to 7.5 months for those receiving best supportive care alone [379]. - The company has ongoing clinical trials, including Phase 3 trials in GBM and NSCLC, to explore the use of TTFields therapy [380]. - The company expects research, development, and clinical expenses to continue increasing over the next several years, potentially outpacing gross profit, indicating a need for additional capital [359]. Strategic Partnerships and Market Position - The company has established coverage policies with public and private payers for Optune Gio and is actively pursuing similar policies for Optune Lua and Optune Pax [378]. - The company has a license agreement with Zai Lab to commercialize its products in Greater China, aimed at accelerating the development of TTFields therapy [382]. - The company is in the final steps of adding production capacity in Mexico and Ireland to enhance supply chain resilience [384].

Core Viewpoint - Novocure (NVCR) has received FDA approval for its portable therapeutic device, Optune Pax, for treating adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel, ahead of the expected timeline of Q2 2026 [1][2] Company Developments - The FDA approval is based on the successful phase III study, PANOVA-3, which showed that Optune Pax combined with gem/nab-pac significantly improved overall survival compared to gem/nab-pac alone [2][9] - Novocure has other commercialized therapies using Tumor Treating Fields (TTFields), including Optune Gio for glioblastoma multiforme and Optune Lua for metastatic non-small cell lung cancer [3] - The company is also developing therapies for treating metastatic pancreatic cancer and newly diagnosed glioblastoma multiforme [3] Clinical Data - The PANOVA-3 study demonstrated a median overall survival (mOS) of 16.2 months for patients treated with Optune Pax and gem/nab-pac, compared to 14.2 months for those receiving gem/nab-pac alone [8][10] - The one-year survival rate was 68.1% for the Optune Pax group versus 60.2% for the gem/nab-pac group [10] - Additionally, the median time to pain progression improved to 15.2 months with Optune Pax compared to 9.1 months for gem/nab-pac alone [10] Market Potential - The pancreatic cancer market is projected to grow from $3.01 billion to $9.57 billion between 2025 and 2034, at a CAGR of 13.7%, driven by increasing cases and advancements in treatment options [12] - The approval of Optune Pax is expected to enhance Novocure's market prospects, given the limited treatment options currently available for pancreatic cancer [12] Financial Performance - Novocure reported preliminary net revenues of $174.4 million for Q4 and full-year 2025, reflecting an 8% year-over-year increase, with total revenues for the year reaching $655 million [13]